Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an expl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4196848?pdf=render |